SCHEMBL4357381

SCHEMBL4357381

CC(=CC=C1SC(N2CCOCC2)=NC1=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.50
ALDH1A1 P00352 9/20 0.50
MDM2 Q00987 1/20 0.50
SMN1; SMN2 Q16637 6/20 0.49
KMT2A Q03164 5/20 0.49
RAB9A P51151 4/20 0.49
MEN1 O00255 4/20 0.49
NPC1 O15118 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C19 P33261 2/20 0.49
HCRTR1 O43613 1/20 0.49
GAA P10253 3/20 0.48
NPSR1 Q6W5P4 3/20 0.46
LMNA P02545 3/20 0.46
HTT P42858 1/20 0.46
HPGD P15428 2/20 0.44
KDM4E B2RXH2 2/20 0.42
RAF1 P04049 1/20 0.41
BRAF P15056 1/20 0.41
PSMD14 O00487 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4357379 1.00 MAPT (0.50) MAPTALDH1A1MDM2SMN1; SMN2KMT2A
SCHEMBL4358503 0.88 MAPT (0.50) MAPTALDH1A1MDM2SMN1; SMN2KMT2A
SCHEMBL4358508 0.88 MAPT (0.50) MAPTALDH1A1MDM2SMN1; SMN2KMT2A
SCHEMBL4364864 0.81 MAPT (0.53) MAPTALDH1A1SMN1; SMN2KMT2ARAB9A
SCHEMBL4364867 0.81 MAPT (0.53) MAPTALDH1A1SMN1; SMN2KMT2ARAB9A
SCHEMBL4346313 0.80 SMN1; SMN2 (0.64) MAPTALDH1A1SMN1; SMN2KMT2ARAB9A
SCHEMBL4346315 0.80 SMN1; SMN2 (0.64) MAPTALDH1A1SMN1; SMN2KMT2ARAB9A
SCHEMBL4354246 0.79 KMT2A (0.63) MAPTALDH1A1MDM2SMN1; SMN2KMT2A
SCHEMBL4354242 0.79 KMT2A (0.63) MAPTALDH1A1MDM2SMN1; SMN2KMT2A
Bromide SCHEMBL4356134 0.78 KMT2A (0.62) MAPTALDH1A1MDM2SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP claimed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US claimed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP claimed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO claimed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 MAPT 1470/4885ALDH1A1 284/4885MDM2 2436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.